Yusuke Chihara

3.1k total citations
60 papers, 898 citations indexed

About

Yusuke Chihara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Yusuke Chihara has authored 60 papers receiving a total of 898 indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 10 papers in Epidemiology. Recurrent topics in Yusuke Chihara's work include Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Yusuke Chihara is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (24 papers). Yusuke Chihara collaborates with scholars based in Japan, United Kingdom and United States. Yusuke Chihara's co-authors include Koichi Takayama, Tadaaki Yamada, Junji Uchino, Yoshiko Kaneko, Nobuyo Tamiya, Yuki Katayama, Masahiro Iwasaku, Takayuki Takeda, Yoshie Morimoto and Takayuki Shimamoto and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Medicine.

In The Last Decade

Yusuke Chihara

58 papers receiving 888 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yusuke Chihara Japan 13 641 435 154 114 86 60 898
Yasuto Yoneshima Japan 17 669 1.0× 482 1.1× 177 1.1× 101 0.9× 84 1.0× 54 944
Yoshiko Kaneko Japan 17 630 1.0× 508 1.2× 241 1.6× 146 1.3× 104 1.2× 59 1.1k
Takaaki Tokito Japan 18 943 1.5× 726 1.7× 198 1.3× 140 1.2× 171 2.0× 92 1.3k
Filippos Koinis Greece 17 684 1.1× 252 0.6× 257 1.7× 286 2.5× 235 2.7× 43 997
Shinichiro Shimamatsu Japan 12 352 0.5× 277 0.6× 175 1.1× 92 0.8× 89 1.0× 40 580
Davide Brocco Italy 14 302 0.5× 75 0.2× 202 1.3× 140 1.2× 107 1.2× 30 586
Jianguo Sun China 18 425 0.7× 333 0.8× 287 1.9× 109 1.0× 173 2.0× 60 921
Ken Saijo Japan 12 232 0.4× 133 0.3× 203 1.3× 50 0.4× 52 0.6× 47 530
Jean‐Laurent Deville France 14 185 0.3× 254 0.6× 191 1.2× 30 0.3× 84 1.0× 38 642
Venessa Chin Australia 14 591 0.9× 167 0.4× 299 1.9× 54 0.5× 222 2.6× 46 916

Countries citing papers authored by Yusuke Chihara

Since Specialization
Citations

This map shows the geographic impact of Yusuke Chihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuke Chihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuke Chihara more than expected).

Fields of papers citing papers by Yusuke Chihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuke Chihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuke Chihara. The network helps show where Yusuke Chihara may publish in the future.

Co-authorship network of co-authors of Yusuke Chihara

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuke Chihara. A scholar is included among the top collaborators of Yusuke Chihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuke Chihara. Yusuke Chihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Katayama, Yuki, Tadaaki Yamada, Kenji Morimoto, et al.. (2023). TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100494–100494. 5 indexed citations
4.
5.
Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2023). Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. Cancers. 15(5). 1543–1543. 7 indexed citations
6.
7.
Yamada, Tadaaki, Satomi Tanaka, Shinsuke Shiotsu, et al.. (2023). Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer. Cancer Medicine. 12(8). 9097–9105. 4 indexed citations
8.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study. Targeted Oncology. 18(5). 657–665. 7 indexed citations
9.
10.
Tanimura, Keiko, Junji Uchino, Hideharu Kimura, et al.. (2023). Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial. The Oncologist. 28(6). 551–e454. 6 indexed citations
11.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388. 5 indexed citations
12.
Morimoto, Kenji, Junji Uchino, Takashi Yokoi, et al.. (2021). Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. OncoImmunology. 10(1). 1950411–1950411. 33 indexed citations
13.
Yamada, Tadaaki, Kenji Morimoto, Akira Nakao, et al.. (2021). Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology. 148(11). 2985–2994. 1 indexed citations
14.
Takeda, Takayuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2021). Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics. 11(12). 2170–2170. 7 indexed citations
15.
Morimoto, Kenji, Tadaaki Yamada, Yuki Katayama, et al.. (2020). Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. Medical Oncology. 37(12). 111–111. 12 indexed citations
16.
Yamada, Tadaaki, Junji Uchino, Yusuke Chihara, et al.. (2020). Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Therapeutic Advances in Medical Oncology. 12. 3863542881–3863542881. 7 indexed citations
17.
Yamada, Tadaaki, Yuki Katayama, Akihiro Yoshimura, et al.. (2019). Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer. Cancer Medicine. 8(4). 1521–1529. 78 indexed citations
18.
Imabayashi, Tatsuya, Junji Uchino, Akihiro Yoshimura, et al.. (2019). Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers. 11(3). 410–410. 31 indexed citations
19.
Katayama, Yuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2019). Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer. Thoracic Cancer. 10(3). 526–532. 16 indexed citations
20.
Nishioka, Naoya, Junji Uchino, Yuki Katayama, et al.. (2019). Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 8(4). 450–450. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuto Yoneshima Breakdown of academic impact, for papers by Yoshiko Kaneko Breakdown of academic impact, for papers by Takaaki Tokito Breakdown of academic impact, for papers by Filippos Koinis Breakdown of academic impact, for papers by Shinichiro Shimamatsu Breakdown of academic impact, for papers by Davide Brocco Breakdown of academic impact, for papers by Jianguo Sun Breakdown of academic impact, for papers by Ken Saijo Breakdown of academic impact, for papers by Jean‐Laurent Deville Breakdown of academic impact, for papers by Venessa Chin
Rankless by CCL
2026